Technology

LinkedIn founder predicts next AI boom after chatbots: Here’s what comes next

Hoffman is the co-founder of Manas AI, a biopharmaceutical company that uses AI for drug discovery

Published May 29, 2026
LinkedIn founder predicts next AI boom after chatbots: Here’s what comes next
LinkedIn founder predicts next AI boom after chatbots: Here’s what comes next

The investor who helped build LinkedIn says the AI chatbot window has already closed. Speaking on The Possible Podcast this week, LinkedIn founder Reid Hoffman told investors to stop chasing OpenAI and Anthropic and start looking at AI-powered medicine instead, describing healthcare as a "massively larger total addressable market" that is only beginning to be disrupted.

The dominant chatbot platforms are already entrenched. OpenAI and Anthropic have captured investor attention and market share to the point where new entrants face an uphill battle.

Advertisement

He noted that although investors continue to be "googly-eyed" about Anthropic’s growth since its run rate passed $47 billion this month, he felt that just because a market achieves scale does not mean there is enough space at the top for new entrants. "Now it's the time for medicine," he quipped.

Hoffman is the co-founder of Manas AI, a biopharmaceutical company that uses AI for drug discovery. Its mission statement is to create a "drug discovery factory for monopolies", an intentionally controversial take on what the company represents.

New drugs usually enjoy a 20-year patent protection, allowing them to earn revenues worth billions. But, according to Hoffman, AI can expedite the beginning stage of this process: making research quicker, less expensive, and more efficient than it has taken decades.

While AI chatbots have concentrated on just a few platforms, Hoffman believes that this won't be the case for healthcare.

Citing the example of GLP-1 drug manufacturers making tens of billions each for their own drugs within the same class, Hoffman believes that there is potential for pharmaceutical AI to create multiple winners at once.

"It's very possible to have a monopoly on your drug and have other drugs even in the same space be really lucrative," he said.

Hoffman has recently disputed the idea that the AI revolution has led to mass layoffs of jobs across tech companies. In his latest post on the platform X, Hoffman noted that many tech firms were conveniently attributing mass layoffs to AI when it was simply due to overhiring during the pandemic period from 2020 to 2023.

"It's important not to ignore other factors," he wrote, a nuanced position that cuts against both AI doom narratives and AI hype cycles simultaneously.

Pareesa Afreen
Pareesa Afreen is a reporter and sub editor specialising in technology coverage, with 3 years of experience. She reports on digital innovation, gadgets, and emerging tech trends while ensuring clarity and accuracy through her editorial role, delivering accessible and engaging stories for a fast-evolving digital audience.
Share this story: